A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.Samantha Jaglowski, John C. Byrd, Michael R. Grever et al.|Journal of Clinical Oncology|2012Cited by 65
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II StudySusan O’Brien, John C. Byrd, Jan A. Burger et al.|Blood|2011Cited by 56
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.Susan O’Brien, Jennifer R. Brown, Jacqueline C. Barrientos et al.|Journal of Clinical Oncology|2012Cited by 36